In this report, the Global Primary Sclerosing Cholangitis Therapeutics Market has been segmented by Drug, Treatment Type and Geography.

Primary Sclerosing Cholangitis Therapeutics Market, Segmentation by Drug

The Primary Sclerosing Cholangitis Therapeutics Market has been segmented by Drug into BTT1023, GS-9674, NGM282, OCA, Cenicriviroc, LUM001, DUR928, norUDCA, HTD1801, IDN-7314, and STP705.

BTT1023

BTT1023 holds a promising share of approximately 12% in the PSC therapeutics pipeline, targeting VAP-1 inhibition to reduce inflammation and fibrosis in bile ducts. It is being evaluated for its ability to modulate immune cell trafficking and prevent disease progression.

GS-9674

GS-9674 contributes around 11% to the pipeline, functioning as an FXR agonist aimed at reducing bile acid toxicity and liver inflammation. It is under clinical investigation for its potential to improve liver enzyme profiles and halt fibrotic damage.

NGM282

NGM282 (aldafermin) represents approximately 10% of the market pipeline, known for its FGF19 analog activity that supports bile acid regulation and anti-inflammatory effects. Early-phase trials suggest improvement in liver histology and biomarker reduction.

OCA

OCA (obeticholic acid) accounts for nearly 9%, acting as a potent FXR agonist to address cholestasis and inflammation. It has shown potential in improving bile flow and is also being studied in related conditions like PBC and NASH.

Cenicriviroc

Cenicriviroc contributes close to 8%, targeting CCR2/CCR5 receptors to modulate immune-mediated fibrosis. It is being explored for its dual anti-inflammatory and anti-fibrotic properties in liver diseases including PSC.

LUM001

LUM001 (maralixibat) makes up about 7% of the pipeline, working as an IBAT inhibitor to reduce bile acid reabsorption and improve pruritus symptoms associated with cholestatic conditions.

DUR928

DUR928 accounts for roughly 7%, a novel epigenetic regulator with anti-inflammatory and anti-fibrotic mechanisms. It is gaining attention for its broad therapeutic potential across hepatic injury models.

norUDCA

norUDCA captures around 6% of the pipeline and is a side chain-shortened bile acid designed to enhance bile flow and reduce toxic bile acid accumulation. It is progressing through advanced clinical stages.

HTD1801

HTD1801 holds approximately 6%, offering dual benefits in liver metabolism and inflammation reduction. It combines berberine and ursodeoxycholic acid, and is under evaluation for PSC and metabolic liver disorders.

IDN-7314

IDN-7314 makes up nearly 5%, being studied as an FXR modulator to reduce bile acid synthesis and improve hepatic inflammation. It is showing potential in early-phase trials.

STP705

STP705 contributes the remaining 4%, a small interfering RNA (siRNA)-based therapy targeting TGF-β1 and COX-2 to combat liver fibrosis and inflammation. It is part of a novel class of gene-silencing therapeutics in liver disease pipelines.

Primary Sclerosing Cholangitis Therapeutics Market, Segmentation by Treatment Type

The Primary Sclerosing Cholangitis Therapeutics Market has been segmented by Treatment Type into Pharmaceutical Therapy, and Surgical Intervention.

Pharmaceutical Therapy

Pharmaceutical therapy dominates the PSC therapeutics market with a share of approximately 70%, driven by increasing clinical trials for anti-fibrotic, anti-inflammatory, and bile acid-modulating agents. Current drug candidates focus on symptom management, delaying disease progression, and reducing the risk of cholangiocarcinoma and liver failure.

Surgical Intervention

Surgical intervention accounts for around 30% of the market, typically reserved for advanced-stage patients. Procedures such as liver transplantation, biliary drainage, and endoscopic therapies are used to manage complications like dominant strictures and end-stage liver disease, often when pharmacological options are no longer effective.

Primary Sclerosing Cholangitis Therapeutics Market, Segmentation by Geography

In this report, the Primary Sclerosing Cholangitis Therapeutics Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Primary Sclerosing Cholangitis Therapeutics Market Share (%), by Geographical Region

North America

North America dominates the PSC therapeutics market with a share of approximately 42%, attributed to a high incidence of inflammatory bowel diseases (IBD), advanced healthcare infrastructure, and strong presence of biopharmaceutical companies. The U.S. leads the region in terms of clinical research and drug pipeline activity.

Europe

Europe holds around 30% of the market, driven by increasing government funding for rare diseases, presence of specialized liver disease centers, and active participation in multinational clinical trials. Countries like Germany and the UK are key contributors to regional growth.

Asia Pacific

Asia Pacific accounts for roughly 15% of the market, with rising awareness of liver disorders, increasing investment in biotechnology, and expanding clinical trial networks. Countries like Japan, China, and South Korea are emerging markets in PSC research and treatment access.

Middle East and Africa

This region represents nearly 7% of the market, with gradual improvements in specialty care facilities and a growing focus on hepatobiliary disease management. Market penetration remains limited due to low disease awareness and healthcare access disparities.

Latin America

Latin America captures about 6% of the global market, supported by improvements in diagnostic capabilities and an increasing number of research collaborations in Brazil, Mexico, and Argentina. However, the availability of advanced therapies remains a challenge across the region.

This report provides an in depth analysis of various factors that impact the dynamics of Global Primary Sclerosing Cholangitis Therapeutics Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunities Analysis

Drivers

• Increasing prevalence of liver diseases
• Advancements in medical research
• Growing healthcare expenditure globally

• Rising awareness about treatment options - Growing awareness about treatment options is a key driver fueling the global primary sclerosing cholangitis (PSC) therapeutics market. Increased patient education, improved physician engagement, and the dissemination of clinical guidelines are encouraging earlier diagnosis and proactive disease management. Patients and healthcare providers are now more informed about experimental therapies, supportive care strategies, and liver transplant protocols, leading to greater treatment uptake and enhanced disease monitoring.

  This rising awareness is also driving demand for participation in clinical trials and investigational drug programs, especially as patients seek alternatives to manage this rare and complex liver disease. Advocacy groups and medical organizations are playing a critical role in disseminating reliable information and connecting patients to emerging therapies. As understanding of PSC grows, so does the momentum for research, investment, and innovation within the therapeutics landscape.

Restraints

• Limited understanding of disease mechanisms
• High cost of treatment
• Stringent regulatory requirements

• Availability of alternative therapies - The availability of alternative therapies remains a significant restraint in the global primary sclerosing cholangitis (PSC) therapeutics market. Although there is no approved curative treatment for PSC, patients often turn to off-label medications, symptomatic management, and lifestyle modifications to control disease progression and alleviate discomfort. These alternatives, while not disease-modifying, may reduce the perceived need for new or experimental therapeutics, particularly in cases where patients show slow disease progression or minimal symptoms.

  Furthermore, the presence of non-pharmacological interventions such as endoscopic procedures, bile acid therapies, and liver transplantation reduces dependency on emerging drug candidates. This diversification in care strategies creates a fragmented treatment landscape, limiting the urgency and scale of therapeutic adoption. As long as these alternative approaches remain widely used and accessible, the uptake of novel therapies may face hesitancy from both patients and healthcare providers.

Opportunities

• Emerging markets in Asia-Pacific
• Development of novel therapeutic approaches
• Collaborations for clinical trials

• Personalized medicine and targeted therapies - The rise of personalized medicine and targeted therapies offers a promising opportunity in the global primary sclerosing cholangitis (PSC) therapeutics market. Advances in genomics, immune profiling, and biomarker research are enabling the development of customized treatments that align with individual disease characteristics. This approach is especially valuable in PSC, where disease progression and treatment responses vary significantly among patients, and current treatment options remain limited.

  Pharmaceutical companies are increasingly focused on creating biologics and targeted small molecules that act on specific inflammatory and fibrotic pathways. These precision therapies can improve clinical outcomes while minimizing side effects, supporting the transition from generalized care to more effective, patient-specific strategies. As regulatory bodies show growing interest in personalized approaches, this trend is expected to drive both innovation and adoption in PSC treatment development.

Key players in Global Primary Sclerosing Cholangitis Therapeutics Market include:

• Intercept Pharmaceuticals, Inc
• Gilead Sciences, Inc
• Allergan plc
• Genfit SA
• Novartis AG
• Pfizer Inc
• Merck & Co., Inc
• Takeda Pharmaceutical Company Limited
• Bristol Myers Squibb
• F Hoffmann-La Roche Ltd

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Market Share Analysis
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis